BACKGROUND: Maintaining a gluten-free diet (GFD) without an underlying diagnosis of celiac disease has enjoyed widespread acceptance in the Unites States. METHODS: We performed a cross-sectional study using a GFD questionnaire in 1647 patients with inflammatory bowel diseases (IBD) participating in the CCFA Partners longitudinal Internet-based cohort. RESULTS: A diagnosis of celiac disease and non-celiac gluten sensitivity were reported by 10 (0.6%) and 81 (4.9%) respondents, respectively. Three hundred fourteen (19.1%) participants reported having previously tried a GFD and 135 (8.2%) reported current use of GFD. Overall 65.6% of all patients, who attempted a GFD, described an improvement of their gastrointestinal symptoms and 38.3% reported fewer or less severe IBD flares. In patients currently attempting a GFD, excellent adherence was associated with significant improvement of fatigue (P < 0.03). CONCLUSIONS: In this large group of patients with IBD, a substantial number had attempted a GFD, of whom the majority had some form of improvement in gastrointestinal symptoms. Testing a GFD in clinical practice in patients with significant intestinal symptoms, which are not solely explained by the degree of intestinal inflammation, has the potential to be a safe and highly efficient therapeutic approach. Further prospective studies into mechanisms of gluten sensitivity in IBD are warranted.
BACKGROUND: Maintaining a gluten-free diet (GFD) without an underlying diagnosis of celiac disease has enjoyed widespread acceptance in the Unites States. METHODS: We performed a cross-sectional study using a GFD questionnaire in 1647 patients with inflammatory bowel diseases (IBD) participating in the CCFA Partners longitudinal Internet-based cohort. RESULTS: A diagnosis of celiac disease and non-celiac gluten sensitivity were reported by 10 (0.6%) and 81 (4.9%) respondents, respectively. Three hundred fourteen (19.1%) participants reported having previously tried a GFD and 135 (8.2%) reported current use of GFD. Overall 65.6% of all patients, who attempted a GFD, described an improvement of their gastrointestinal symptoms and 38.3% reported fewer or less severe IBD flares. In patients currently attempting a GFD, excellent adherence was associated with significant improvement of fatigue (P < 0.03). CONCLUSIONS: In this large group of patients with IBD, a substantial number had attempted a GFD, of whom the majority had some form of improvement in gastrointestinal symptoms. Testing a GFD in clinical practice in patients with significant intestinal symptoms, which are not solely explained by the degree of intestinal inflammation, has the potential to be a safe and highly efficient therapeutic approach. Further prospective studies into mechanisms of gluten sensitivity in IBD are warranted.
Authors: Antonio Carroccio; Pasquale Mansueto; Giuseppe Iacono; Maurizio Soresi; Alberto D'Alcamo; Francesca Cavataio; Ignazio Brusca; Ada M Florena; Giuseppe Ambrosiano; Aurelio Seidita; Giuseppe Pirrone; Giovanni Battista Rini Journal: Am J Gastroenterol Date: 2012-07-24 Impact factor: 10.864
Authors: Ashwin N Ananthakrishnan; Millie D Long; Christopher F Martin; Robert S Sandler; Michael D Kappelman Journal: Clin Gastroenterol Hepatol Date: 2013-02-01 Impact factor: 11.382
Authors: Maria I Vazquez-Roque; Michael Camilleri; Thomas Smyrk; Joseph A Murray; Eric Marietta; Jessica O'Neill; Paula Carlson; Jesse Lamsam; Denise Janzow; Deborah Eckert; Duane Burton; Alan R Zinsmeister Journal: Gastroenterology Date: 2013-01-25 Impact factor: 22.682
Authors: Anna Sapone; Julio C Bai; Carolina Ciacci; Jernej Dolinsek; Peter H R Green; Marios Hadjivassiliou; Katri Kaukinen; Kamran Rostami; David S Sanders; Michael Schumann; Reiner Ullrich; Danilo Villalta; Umberto Volta; Carlo Catassi; Alessio Fasano Journal: BMC Med Date: 2012-02-07 Impact factor: 8.775
Authors: Arlene E Chung; Robert S Sandler; Millie D Long; Sean Ahrens; Jessica L Burris; Christopher F Martin; Kristen Anton; Amber Robb; Thomas P Caruso; Elizabeth L Jaeger; Wenli Chen; Marshall Clark; Kelly Myers; Angela Dobes; Michael D Kappelman Journal: J Am Med Inform Assoc Date: 2016-01-28 Impact factor: 4.497
Authors: James D Lewis; Lindsey Albenberg; Dale Lee; Mario Kratz; Klaus Gottlieb; Walter Reinisch Journal: Inflamm Bowel Dis Date: 2017-02 Impact factor: 5.325